Join to View Full Profile
4500 San Pablo Road SJacksonville, FL 32224
Dr. Roy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Vivek Roy is a hematologist based in Jacksonville, FL, with specialized expertise in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hematopoietic stem cell transplantation. He completed his internal medicine residency at UMass Chan Medical School and a fellowship in hematology and medical oncology at the University of Minnesota. His education began at the All India Institute of Medical Sciences, Class of 1980. Dr. Roy has contributed to multiple publications in prominent journals like Bone Marrow Transplantation and Blood Cancer Journal. His research also includes significant clinical trials, such as those on multiple myeloma treatment. He has received various CMS Meaningful Use Certifications from Cerner Corporation.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1993 - 1996
UMass Chan Medical SchoolResidency, Internal Medicine, 1991 - 1993
All India Institute of Medical SciencesClass of 1980
Certifications & Licensure
AZ State Medical License 2000 - Present
FL State Medical License 2001 - 2027
MN State Medical License 1994 - 2027
OK State Medical License 1996 - 2005
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification FirstNet, Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart, Cerner Corporation, 2013-2015, 2017
Clinical Trials
- Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Start of enrollment: 2005 Aug 01
- ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer Start of enrollment: 2005 Aug 01
- Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Start of enrollment: 2003 Jul 01
Publications & Presentations
PubMed
- Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and Dexamethasone.Ricardo D Parrondo, Ricardo C B de Menezes, Hanna Sledge, Madhavi Nayyar, Kanika Yadav
American Journal of Hematology. 2026-04-01 - Post-transplant Cyclophosphamide Reduces Bronchiolitis Obliterans Syndrome Risk Through Chronic Graft-versus-Host Disease Prevention: A Multicenter Cohort Study.Reid H Eggleston, Hassan Alkhateeb, Kelly M Pennington, Zhenmei Zhang, Mehrdad Hefazi Torghabeh
Chest. 2026-03-16 - Effect of Somatic Variants Post Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.Madiha Iqbal, Himil Mahadevia, Zhuo Li, Sophia Blumenfeld, Hemant Murthy
Hematology/oncology and Stem Cell Therapy. 2026-03-13
Journal Articles
- Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia CellsRichard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
- Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Abstracts/Posters
- Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based AnalysisVivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Sociodemographic and Clinical Characteristics Associated with PatientÍs Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on OutcomesVivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Sharing Mayo Clinic: “Divine Design” Gives Multiple Myeloma Patient Transplant, Care at HomeSeptember 5th, 2021- “Divine Design” Gives Multiple Myeloma Patient Transplant, Care at HomeSeptember 2nd, 2021
- NCCN Releases New Patient Guidelines on Anemia and NeutropeniaMay 3rd, 2021
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
